Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of PVLA is 182 and suggests 122% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell